GILD•benzinga•
Gilead Showcases Livdelzi's Efficacy And Tolerability In PBC, With 60% Response Rate Among Patients With Prior Fibrate Or OCA Use, At EASL 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 7, 2025 by benzinga